Board of Directors

Michael Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank. Prior to this, he was the Chief Financial Officer of Trek Therapeutics, a development-stage pharmaceutical company. Mr. Bator served as Managing Director of Healthcare Research at Jennison Associates, a US-based mutual and pension fund management company that currently manages $175 billion in assets. During his 14 years at Jennison, Mr. Bator evaluated and recommended a wide array of investments in medical devices, European pharmaceuticals, managed-care companies, and many others, including well-known companies such as Medtronic, Abbott, Baxter, Johnson and Johnson, Novartis, AstraZeneca, Roche, and GSK.

Mr. Bator also has extensive management consulting experience, having spent many years with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University.

Dr. Phillip Chan is the Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO). Over the past 16 years, Dr. Chan has led the company through the EU approval and commercialization of its flagship product, CytoSorb, as a novel blood purification therapy to treat cytokine storm and control potentially deadly inflammation seen in life-threatening illnesses in the intensive care unit and cardiac surgery.

Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the largest seed and Series A early-stage venture investors in the greater New York region, and a top 1% performing fund for its vintage.

Dr. Chan is also a co-founder and Vice Chairman of Medality Medical, formerly known as Andrew Technologies, a privately-held medical device company pursuing a surgical cure of Type 2 diabetes through removal of deep mesenteric metabolic fat with its FDA-approved lipoplasty system HydraSolve™.

Dr. Chan received board certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/PhD from Yale University School of Medicine and his BSc in cell and molecular biology from Cornell University.

Prior to his retirement in 2020, Edward Jones, MD, MBA was an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital. Dr. Jones was a practicing nephrologist as well as Medical Director of a dialysis facility for Fresenius Medical Care. He taught renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine. Dr. Jones is a highly respected member of the renal research community.

He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He has been a member of the Renal Physicians Association and the Philadelphia County Medical Society for 17 years and is a past board member of the National Kidney Foundation of the Delaware Valley. Dr. Jones is Past President of the Renal Physicians Association.

Alan D. Sobel was previously the Managing Member of Sobel & Co., LLC, a Livingston, NJ based full-service accounting, auditing, taxation, and business consulting firm with a diverse clientele including small and mid-sized businesses, non-profit agencies, SEC-registered companies, and individuals, prior to its acquisition by CliftonLarsonAllen LLP (CLA) – the 8^th largest accounting firm in the United States. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, amongst others.

Alan is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. He earned a Bachelor of Science degree in Accountancy from Bentley College, and a Master of Science in Taxation from Fairleigh Dickinson University.

Ms. Kim is currently a Vice President at Zimmer Biomet, where she serves as the general manager of the Smart Implants portfolio and is responsible for leading the end-to-end program and product management for Zimmer Biomet’s Smart Implants technology in the orthopedic field. Previously, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Depression at LivaNova from 2020 to 2021. Prior to LivaNova, from 2011 to 2020, Ms. Kim served in increasing roles of responsibility at Johnson & Johnson Medical Devices. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences.